TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15642751

Group type: EXPERIMENTAL
Intervention: Health promotion/occupational health program (HP/OHS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard intervention (HP)
Number of subjects: 0
Study: 12456545

Group type: EXPERIMENTAL
Intervention: Hospital at Home (HAH)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Conventional inpatient care
Number of subjects: 399

Group type: COMPARATOR
Intervention: NHS costs
Number of subjects: 399
Study: 10472581

Group type: EXPERIMENTAL
Intervention: Artesunate
Number of subjects: 30
Study: 8734749

Group type: EXPERIMENTAL
Intervention: Ventricular pacing (VVI)
Number of subjects: 11
Study: 1661696

Group type: EXPERIMENTAL
Intervention: Active direct current electrotherapy
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 16
Study: 6256423

Group type: EXPERIMENTAL
Intervention: Theophylline (therapeutic doses given intravenously and orally over 3 days)
Number of subjects: 10
Study: 31926597

Group type: EXPERIMENTAL
Intervention: Total Intravenous Anaesthesia (TIVA)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Low-flow sevoflurane anaesthesia (SEVO)
Number of subjects: 90
Study: 31185808

Group type: EXPERIMENTAL
Intervention: Goal setting
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Self-talk
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no systematic psychological method)
Number of subjects: 49
Study: 28455746

Group type: EXPERIMENTAL
Intervention: Cervical headgear treatment
Number of subjects: 41

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 41
Study: 25712577

Group type: EXPERIMENTAL
Intervention: 400 μg of misoprostol (n = 30)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 10 mg of dinoprostone (n = 30)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo group (n = 30)
Number of subjects: 90
Study: 23873791

Group type: EXPERIMENTAL
Intervention: Coated nickel-titanium wires
Number of subjects: 61

Group type: COMPARATOR
Intervention: Regular nickel-titanium wires (non-coated)
Number of subjects: 61
Study: 23066842

Group type: EXPERIMENTAL
Intervention: LCPUFA supplementation
Number of subjects: 474

Group type: COMPARATOR
Intervention: Breastfeeding
Number of subjects: 474
Study: 18987964

Group type: EXPERIMENTAL
Intervention: Comprehensive radiation safety program (group-II)
Number of subjects: 41

Group type: COMPARATOR
Intervention: No safety program (group-I)
Number of subjects: 41
Study: 17414237

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (15‐mg patch, 4‐mg gum, and/or 10‐mg inhaler)
Number of subjects: 923

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 923

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 923

Group type: EXPERIMENTAL
Intervention: Reduction of cigarette consumption by at least 50% between baseline and 6 months
Number of subjects: 923
Study: 16366083

Group type: EXPERIMENTAL
Intervention: Intramedullary cutting guide
Number of subjects: 55

Group type: COMPARATOR
Intervention: Extramedullary cutting guide
Number of subjects: 55
Study: 12410126

Group type: EXPERIMENTAL
Intervention: Inhibitor of specific tyrosine kinase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 9857531

Group type: EXPERIMENTAL
Intervention: Sera containing specific antibodies for Staphylococcus aureus and Escherichia coli obtained from immunized rabbits
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Autologous bacterial strains incubated with asthmatic patients' sera collected after autovaccines treatment
Number of subjects: 18

Group type: COMPARATOR
Intervention: Anti-IgE antibodies
Number of subjects: 18

Group type: COMPARATOR
Intervention: Non-specific sera
Number of subjects: 18
Study: 7597434

Group type: EXPERIMENTAL
Intervention: Paclitaxel (Taxol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paclitaxel combined with cisplatin or carboplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0
Study: 2404053

Group type: EXPERIMENTAL
Intervention: Physician feedback intervention group (38 patients)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (41 patients)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Physician compliance with recommendations
Number of subjects: 89
Study: 43650

Group type: EXPERIMENTAL
Intervention: Thoracic epidural block followed by intravenous prenalterol administration prior to induction of general anaesthesia
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no specific treatment prior to general anaesthesia)
Number of subjects: 16
Study: 31311386

Group type: EXPERIMENTAL
Intervention: adalimumab + MTX
Number of subjects: 4568

Group type: COMPARATOR
Intervention: adalimumab
Number of subjects: 4568

Group type: EXPERIMENTAL
Intervention: adalimumab - MTX
Number of subjects: 4568
Study: 29879249

Group type: EXPERIMENTAL
Intervention: Topical oxymetazoline cream 1.0%
Number of subjects: 885

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 885
Study: 27007800

Group type: EXPERIMENTAL
Intervention: Gabapentin (600 mg preoperatively, one hour prior to surgery)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (Control Group)
Number of subjects: 40
Study: 24491375

Group type: EXPERIMENTAL
Intervention: MESNA applied intraoperatively (46 patients)
Number of subjects: 141

Group type: COMPARATOR
Intervention: MESNA not applied (95 patients)
Number of subjects: 141
Study: 22768902

Group type: EXPERIMENTAL
Intervention: Olibra™ fat emulsion (2.1 g twice daily)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo (1.95 g milk fat, twice daily)
Number of subjects: 82
Study: 19417772

Group type: EXPERIMENTAL
Intervention: Moderate-intensity programme with physician meetings, physical activity prescriptions, group counselling and bicycles
Number of subjects: 120

Group type: COMPARATOR
Intervention: Low-intensity group support programme with pedometers
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study: 17495770

Group type: EXPERIMENTAL
Intervention: ProDisc-L (Synthes Spine) lumbar total disc replacement
Number of subjects: 286

Group type: COMPARATOR
Intervention: Circumferential spinal fusion
Number of subjects: 286
Study: 15638100

Group type: EXPERIMENTAL
Intervention: Ibopamine 2% eye drops
Number of subjects: 40

Group type: COMPARATOR
Intervention: Phenylephrine 10% eye drops
Number of subjects: 40
Study: 11355378

Group type: COMPARATOR
Intervention: Younger subjects (aged 20-32 years)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Older subjects (aged 58-69 years)
Number of subjects: 23
Study: 9558034

Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 7988250

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin (CAP) - 400 mg/m2 of cyclophosphamide, 40 mg/m2 of doxorubicin, and 60 mg/m2 of cisplatin, administered in four courses at 3-week intervals starting 30 days post-surgery.
Number of subjects: 269

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 269
Study: 2660374

Group type: EXPERIMENTAL
Intervention: Tablets with normal particle size
Number of subjects: 8

Group type: COMPARATOR
Intervention: Tablets with coarse particle size
Number of subjects: 8
Study: 4600903

Group type: EXPERIMENTAL
Intervention: Idoxuridine 5% in 100% dimethyl sulphoxide (DMSO), applied four-hourly for four days
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Idoxuridine 25%, applied two-hourly
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 118
Study: 31804851

Group type: EXPERIMENTAL
Intervention: Insulin Aspart Biosimilar SAR341402 (SAR‐Asp)
Number of subjects: 597

Group type: COMPARATOR
Intervention: Originator Insulin Aspart (NN‐Asp)
Number of subjects: 597
Study: 31162653

Group type: EXPERIMENTAL
Intervention: Open minimal suture repair
Number of subjects: 65

Group type: COMPARATOR
Intervention: Totally extraperitoneal repair
Number of subjects: 65
Study: 29330984

Group type: EXPERIMENTAL
Intervention: Polydioxanone
Number of subjects: 620

Group type: COMPARATOR
Intervention: Polypropylene
Number of subjects: 620
Study: 26569492

Group type: EXPERIMENTAL
Intervention: Insecticide Treated Nets (ITN) + Indoor Residual Spraying (IRS)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Insecticide Treated Nets (ITN)
Number of subjects: 160
Study: 23635731

Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20 mg and conjugated estrogens 0.45 mg
Number of subjects: 1843

Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20 mg and conjugated estrogens 0.625 mg
Number of subjects: 1843

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1843

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens 0.45 mg and medroxyprogesterone acetate 1.5 mg
Number of subjects: 1843
Study: 21332430

Group type: EXPERIMENTAL
Intervention: Salbutamol plus ipratropium
Number of subjects: 97

Group type: COMPARATOR
Intervention: Salbutamol only
Number of subjects: 97
Study: 19059639

Group type: EXPERIMENTAL
Intervention: Artesunate
Number of subjects: 12068

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12068
Study: 17067970

Group type: EXPERIMENTAL
Intervention: Early supported discharge
Number of subjects: 62

Group type: COMPARATOR
Intervention: Ordinary stroke unit service
Number of subjects: 62
Study: 14599711

Group type: EXPERIMENTAL
Intervention: GLP-2 (0.75 pmol kg(‐1) min(‐1))
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GLP-2 (2.25 pmol kg(‐1) min(‐1))
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 8
Study: 16792584

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (SIT) for 3 years
Number of subjects: 183

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 183
Study: 10479132

Group type: EXPERIMENTAL
Intervention: Sargramostim 3 times a week for 8 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo 3 times a week for 8 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sargramostim
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Indinavir pharmacokinetics
Number of subjects: 20
Study: 9110067

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir maintenance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous ganciclovir
Number of subjects: 0
Study: 1937663

Group type: EXPERIMENTAL
Intervention: Unfiltered boiled coffee (caffeine content 860 mg/l)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Boiled-and-filtered coffee (caffeine content 887 mg/l)
Number of subjects: 64

Group type: COMPARATOR
Intervention: No coffee (replaced by fruit juice and mineral water)
Number of subjects: 64
Study: 6289857

Group type: EXPERIMENTAL
Intervention: MK421 (enalapril maleate)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: MK521
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31135692

Group type: EXPERIMENTAL
Intervention: REP+EF
Number of subjects: 169

Group type: COMPARATOR
Intervention: REP+EF/IF
Number of subjects: 169
Study: 29329924

Group type: EXPERIMENTAL
Intervention: Dark chocolate (cocoa >85%)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Milk chocolate (cocoa <35%)
Number of subjects: 19
Study: 26093823

Group type: EXPERIMENTAL
Intervention: Exposure Therapy (ET)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Wait List (WL) Control
Number of subjects: 73
Study: 24372004

Group type: EXPERIMENTAL
Intervention: Agomelatine 25 mg
Number of subjects: 72
Study: 22845421

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) session before periodontal treatment
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no MI session)
Number of subjects: 44
Study: 19201327

Group type: EXPERIMENTAL
Intervention: Sealant (Light Bond fluoride‐releasing sealant, Reliance Orthodontic Products)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Self-etching primer (Transbond Plus, 3M Unitek)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (no enamel treatment)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Self-etching primer (SEP)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sealant
Number of subjects: 120
Study: 17484067

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg for 3 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (for 3 days)
Number of subjects: 0
Study: 15383885

Group type: EXPERIMENTAL
Intervention: Dermabond (octylcyanoacrylate)
Number of subjects: 37

Group type: COMPARATOR
Intervention: 4.0 Mononylon continuous subcuticular suture
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both interventions (Dermabond and suture)
Number of subjects: 37
Study: 11799306

Group type: EXPERIMENTAL
Intervention: Rhubarb-sage cream (23 mg/g rhubarb extract, 23 mg/g sage extract)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Sage cream (23 mg/g sage extract)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Zovirax cream (50 mg/g aciclovir)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Zovirax cream
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Rhubarb-sage cream
Number of subjects: 145
Study: 9563211

Group type: EXPERIMENTAL
Intervention: Tolfenamic acid
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study: 7919069

Group type: EXPERIMENTAL
Intervention: Anticoagulation (INR 1.5 to 4.0)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Warfarin (INR 2 - 3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31197107

Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: RT combined with protein and vitamin supplementation (RTS)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Cognitive training (CT)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (20 µg/d)
Number of subjects: 117
Study: 28331003

Group type: EXPERIMENTAL
Intervention: Taselisib 3-16 mg once-daily capsule
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Taselisib 12 mg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Taselisib (any dose)
Number of subjects: 34
Study: 26555157

Group type: EXPERIMENTAL
Intervention: Imagery Rescripting (IR)
Number of subjects: 25

Group type: COMPARATOR
Intervention: No-Intervention Control (no-IR)
Number of subjects: 25
Study: 23945571

Group type: EXPERIMENTAL
Intervention: IM gentamicin OD and oral amoxicillin twice daily for 7 days
Number of subjects: 2250

Group type: EXPERIMENTAL
Intervention: IM penicillin and gentamicin OD for 2 days, followed by oral amoxicillin twice daily for 5 days
Number of subjects: 2250

Group type: COMPARATOR
Intervention: 7 days of once‐daily (OD) intramuscular (IM) procaine penicillin and gentamicin
Number of subjects: 2250
Study: 21685374

Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg daily plus Pegylated IFN-α2b 50 μg weekly
Number of subjects: 112

Group type: COMPARATOR
Intervention: Imatinib 400 mg daily monotherapy
Number of subjects: 112
Study: 18436182

Group type: EXPERIMENTAL
Intervention: Sublingual hyoscyamine spray (0.25 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 100
Study: 16494628

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (150 mg)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303

Group type: COMPARATOR
Intervention: Testosterone (250 mg)
Number of subjects: 303
Study: 12931748

Group type: EXPERIMENTAL
Intervention: Topical antihistamine (4 times daily)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Topical lodoxamide (4 times daily)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Topical corticosteroids
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Topical cyclosporine 0.5% (4 times daily)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Topical cyclosporine compared to topical corticosteroids
Number of subjects: 5
Study: 10980901

Group type: EXPERIMENTAL
Intervention: Standard doses of ACE inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin II type I receptor blockade (ARB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher-than-standard doses of ACE inhibitors
Number of subjects: 0
Study: 9183781

Group type: EXPERIMENTAL
Intervention: Packy & Marlon (treatment group)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Entertainment video game (control group)
Number of subjects: 59
Study: 8473539

Group type: EXPERIMENTAL
Intervention: Listerine rinse for 30 seconds
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Listerine rinse for 60 seconds
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control mouthrinse for 30 seconds
Number of subjects: 94
Study: 3537787

Group type: EXPERIMENTAL
Intervention: 13‐cis‐retinoic acid (24 patients)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (20 patients)
Number of subjects: 44
Study: 29680213

Group type: EXPERIMENTAL
Intervention: Frequent changes in position (group A)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Back massage (group B)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 80
Study: 26016892

Group type: EXPERIMENTAL
Intervention: Hypoxic exercise training (H group)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normoxic exercise training (N group)
Number of subjects: 14
Study: 25016274

Group type: EXPERIMENTAL
Intervention: Manual Therapy (Maitland joint mobilization)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Electrophysical Agents (TENS and cold pack)
Number of subjects: 50
Study: 22173575

Group type: EXPERIMENTAL
Intervention: Grazing (at least 100 kcals every 2-3 hours)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Grazing
Number of subjects: 51

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 51
Study: 20719727

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg daily for at least 1 month preoperatively
Number of subjects: 130

Group type: COMPARATOR
Intervention: No atorvastatin preoperatively
Number of subjects: 130
Study: 18812884

Group type: EXPERIMENTAL
Intervention: Remifentanil at 0.10 microg/kg/min
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Remifentanil at 0.21 microg/kg/min
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Remifentanil at 0.13 microg/kg/min
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Remifentanil at 0.19 microg/kg/min
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Remifentanil at 0.17 microg/kg/min
Number of subjects: 132
Study: 15909491

Group type: EXPERIMENTAL
Intervention: Tetrofosmin (TF) SPECT imaging
Number of subjects: 19

Group type: COMPARATOR
Intervention: MIBI SPECT imaging
Number of subjects: 19
Study: 12552338

Group type: EXPERIMENTAL
Intervention: (90)Y-DOTATOC at 5.55 GBq/cycle
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: (90)Y-DOTATOC at 5.18 GBq/cycle
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Amino acid infusion (lysine +/- arginine)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: (90)Y-DOTATOC at 5 GBq/cycle
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Delayed kidney toxicity
Number of subjects: 40
Study: 11783197

Group type: EXPERIMENTAL
Intervention: Dachengqi Granule (DCQG)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Routine western management
Number of subjects: 35
Study: 8609343

Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor-alpha levels in patients in functional classes I to III (1.95 +/- 0.54, 2.63 +/- 0.48, 6.4 +/- 1.9 pg/ml)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interleukin-6 levels in patients in functional classes I to III (3.3 +/- 0.55, 6.2 +/- 1.1, 5.22 +/- 0.9 pg/ml)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cox proportional-hazards analysis for plasma tumor necrosis factor-alpha
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cox proportional-hazards analysis for plasma interleukin-6
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation of atrial natriuretic factor with circulating tumor necrosis factor-alpha levels
Number of subjects: 0
Study: 1938751

Group type: EXPERIMENTAL
Intervention: Forced oscillation technique (infant-adapted)
Number of subjects: 17
Study: 6279521

Group type: EXPERIMENTAL
Intervention: pivmecillinam/pivampicillin
Number of subjects: 40

Group type: COMPARATOR
Intervention: pivmecillinam alone
Number of subjects: 40
Study: 31888736

Group type: EXPERIMENTAL
Intervention: Nintendo® Wii-based motor activities
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-Wii motor activities
Number of subjects: 0
Study: 29680009

Group type: EXPERIMENTAL
Intervention: Hydrogel spacer placement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrogel spacer
Number of subjects: 0
Study: 27555222

Group type: EXPERIMENTAL
Intervention: Acupuncture (10 sessions)
Number of subjects: 24
Study: 24836122

Group type: EXPERIMENTAL
Intervention: Demanding condition (deliberation about a personal decision problem)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nondemanding control condition
Number of subjects: 0
Study: 22425616

Group type: EXPERIMENTAL
Intervention: Mere exposure (n=32)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Flavour-flavour learning (n=33)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Flavour-nutrient learning (n=39)
Number of subjects: 104
Study: 20373924

Group type: EXPERIMENTAL
Intervention: 1 litre of isotonic energy-drink
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo-drink
Number of subjects: 213
Study: 18725484

Group type: EXPERIMENTAL
Intervention: Metoprolol (beta(1)-selective adrenergic blocker)
Number of subjects: 25
Study: 15944537

Group type: EXPERIMENTAL
Intervention: Exercise stress myocardial perfusion imaging (MPI)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Dipyridamole stress myocardial perfusion imaging (MPI)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Exercise stress MPI
Number of subjects: 16

Group type: COMPARATOR
Intervention: Dipyridamole stress MPI
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Exercise stress MPI and dipyridamole stress MPI
Number of subjects: 16
Study: 12956497

Group type: EXPERIMENTAL
Intervention: Distal cantilever resin‐bonded fixed partial dentures (FPD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bilateral free‐end saddle removable partial dentures (RPD)
Number of subjects: 60
Study: 11764120

Group type: EXPERIMENTAL
Intervention: Variglass VLC (polyacid-modified resin) as an occlusal sealant
Number of subjects: 185